NYSEARCA:IHE iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News → Strange new buyer driving up gold (From Stansberry Research) (Ad) Free IHE Stock Alerts $62.94 -0.16 (-0.25%) (As of 03:34 PM ET) Add Compare Share Share Today's Range$62.78▼$63.2150-Day Range$63.10▼$69.5552-Week Range$55.36▼$69.56Volume66,407 shsAverage Volume73,118 shsMarket Capitalization$129.03 millionAssets Under Management$653.02 millionDividend Yield5.93%Net Expense Ratio0.39% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get iShares U.S. Pharmaceuticals ETF alerts: Email Address About iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors.Read More IHE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IHE ETF News HeadlinesApril 17, 2024 | finance.yahoo.comJNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in FocusApril 10, 2024 | msn.comThis weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?April 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."April 4, 2024 | msn.comUnified Action: Biden and Sanders Target Pharma PricingMarch 18, 2024 | seekingalpha.comIHI: Technological Advances Will Continue Carrying This High-Performing Medical ETFFebruary 14, 2024 | msn.comShould You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?February 7, 2024 | finance.yahoo.comETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings BeatJanuary 31, 2024 | uk.investing.comiShares U.S. Pharmaceuticals ETF (IHE)April 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."January 31, 2024 | seekingalpha.comEIS: A Strong Recovery PlaySee More Headlines Receive IHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssueriShares Fund NameiShares U.S. Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IHE Inception Date5/1/2006 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason Webwww.iShares.com PhoneN/AFund Focus Asset ClassEquity BenchmarkDow Jones U.S. Select Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings38 Fund Statistics Assets Under Management$653.02 million Average Daily Volume$93,352.30 Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorCitibank, N.A. AdvisorBlackRock Fund Advisors CustodianCitibank, N.A. DistributorBlackRock Investments, LLC Transfer AgentCitibank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume6 Put Options16 Call Options6 Short Interest86,600 shs Miscellaneous Outstanding Shares2,050,000Beta0.70 Creation Unit50,000 Creation Fee$306.00 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Ad Stansberry ResearchStrange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today. iShares U.S. Pharmaceuticals ETF ExpensesTypeIHEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.39%0.56%0.54%0.50%0.51%Other Expenses0.00%0.40%0.54%0.64%0.58%Total Expense0.39%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.53%-0.55%-0.68%-0.57%Net Expense0.39%0.60%0.60%0.58%0.58% iShares U.S. Pharmaceuticals ETF (IHE) Holdings & ExposureTop 10 IHE HoldingsEli Lilly and Company(NYSE:LLY)Holding Weight: 24.95%Johnson & Johnson(NYSE:JNJ)Holding Weight: 22.68%Zoetis(NYSE:ZTS)Holding Weight: 4.83%Viatris(NASDAQ:VTRS)Holding Weight: 4.74%Merck & Co., Inc.(NYSE:MRK)Holding Weight: 4.06%Bristol-Myers Squibb(NYSE:BMY)Holding Weight: 3.93%Pfizer(NYSE:PFE)Holding Weight: 3.84%Royalty Pharma(NASDAQ:RPRX)Holding Weight: 3.78%Jazz Pharmaceuticals(NASDAQ:JAZZ)Holding Weight: 3.06%Catalent(NYSE:CTLT)Holding Weight: 2.95%IHE Sector ExposureIHE Industry ExposureFull Holdings Details Key ExecutivesGeorge G. C. Parker Ph.D. (Age 78)Independent Chairman of the Board of Trustees Michael Arthur Latham (Age 51)President, Trustee Jack Gee (Age 57)Chief Financial Officer, Treasurer Geoffrey D. FlynnChief Operating Officer, Executive Vice PresidentAmy Schioldager (Age 56)Executive Vice President Ira P. Shapiro (Age 52)Vice President, Chief Legal Officer Matt TuckerVice PresidentEilleen M. Clavere (Age 61)Secretary Cecilia H. Herbert (Age 68)Independent Trustee Charles A. Hurty (Age 73)Independent Trustee More ExecutivesSimilar ETFsVanEck Pharmaceutical ETFNASDAQ:PPHiShares U.S. Healthcare Providers ETFNYSEARCA:IHFVanEck Biotech ETFNASDAQ:BBHDirexion Daily S&P Biotech Bull 3x SharesNYSEARCA:LABUInvesco S&P 500 Equal Weight Health Care ETFNYSEARCA:RSPHInstitutional OwnershipWealthcare Advisory Partners LLCBought 3,902 shares on 4/15/2024Ownership: 0.190%Matthew Goff Investment Advisor LLCBought 2,410 shares on 4/11/2024Ownership: 0.176%Trust Co. of VermontSold 400 shares on 3/8/2024Ownership: 0.010%Fisher Asset Management LLCBought 1,185,696 shares on 3/5/2024Ownership: 58.879%Goldman Sachs Group Inc.Sold 10,104 shares on 3/1/2024Ownership: 0.658%View All Institutional Transactions IHE ETF - Frequently Asked Questions How have IHE shares performed in 2024? iShares U.S. Pharmaceuticals ETF's stock was trading at $61.80 on January 1st, 2024. Since then, IHE shares have increased by 1.8% and is now trading at $62.94. View the best growth stocks for 2024 here. What does IHE invest in? iShares U.S. Pharmaceuticals ETF is a equity fund issued by iShares. IHE focuses on health care investments and follows the Dow Jones U.S. Select Pharmaceuticals Index. The fund's investments total to approximately $653.02 million assets under management. What stocks does iShares U.S. Pharmaceuticals ETF hold? IHE invests in 38 holdings. Some of the stocks in their portfolio include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Zoetis (ZTS), Viatris (VTRS), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Pfizer (PFE), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). What is the management fee for iShares U.S. Pharmaceuticals ETF? iShares U.S. Pharmaceuticals ETF's management fee is 0.39% and has no other recorded expenses or fee waivers. The net expense ratio for IHE is 0.39%. When did iShares U.S. Pharmaceuticals ETF's stock split? iShares U.S. Pharmaceuticals ETF's stock split on the morning of Thursday, March 7th 2024. The 3-1 split was announced on Thursday, March 7th 2024. The newly created shares were payable to shareholders after the closing bell on Thursday, March 7th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other iShares U.S. Pharmaceuticals ETF investors own include United Parcel Service (UPS), CVS Health (CVS), Genuine Parts (GPC), Intel (INTC), Kinder Morgan (KMI), Wells Fargo & Company (WFC), Archer-Daniels-Midland (ADM), BP (BP) and Campbell Soup (CPB). Who are iShares U.S. Pharmaceuticals ETF's major shareholders? iShares U.S. Pharmaceuticals ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wealthcare Advisory Partners LLC (0.19%) and Matthew Goff Investment Advisor LLC (0.18%). How do I buy shares of iShares U.S. Pharmaceuticals ETF? Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:IHE) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm PressHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares U.S. Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.